✦ LIBER ✦

Effect of the V1a/V2-AVP receptor antagonist, Conivaptan, on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascites

✍ Scribed by Guillermo Fernández-Varo; Josefa Ros; Pilar Cejudo-Martı́n; Carmen Cano; Vicente Arroyo; Francisca Rivera; Juan Rodés; Wladimiro Jiménez

Book ID: 118565979
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 329 KB
Volume: 38
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(03)00116-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Sustained aquaretic effect of the V2-AVP

Sustained aquaretic effect of the V2-AVP receptor antagonist, RWJ-351647, in cirrhotic rats with ascites and water retention

✍ Josefa Ros; Guillermo Fernández-Varo; Javier Muñoz-Luque; Vicente Arroyo; Juan R 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 177 KB

Acute hemodynamic effects of conivaptan,

Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure

✍ J.E. Udelson; W.B. Smith; G.H. Hendrix 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 33 KB

Cardiovascular and renal effects of coni

Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure

✍ Takeyuki Yatsu; Yuichi Tomura; Atsuo Tahara; Koh-ichi Wada; Toshiyuki Kusayama; 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 466 KB

Effects of satavaptan, a selective vasop

Effects of satavaptan, a selective vasopressin V2 receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: A randomized trial

✍ Pere Ginès; Florence Wong; Hugh Watson; Slobodan Milutinovic; Luis Ruiz del Arbo 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB 👁 1 views

Hyponatremia in cirrhosis is associated with significant morbidity and mortality and complicates ascites management. Vasopressin receptor antagonists improve serum sodium concentration by increasing renal solute-free water excretion, but their effects on the management of ascites have not been asses

732 Effects of satavaptan (SR121463B), a

732 Effects of satavaptan (SR121463B), a selective vasopressin V2 receptor antagonist, on serum sodium concentration and ascites in patients with cirrhosis and hyponatraemia

✍ P. Gines; F. Wong; S. Milutinovic; L. Ruiz del Arbol; D. Olteanu 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 114 KB

Clinical trial: short-term effects of co

Clinical trial: short-term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia – a randomized, double-blind, placebo-controlled study

✍ P. GINÈS; F. WONG; H. WATSON; R. TERG; R. BRUHA; J.-P. ZARSKI; F. DUDLEY; FOR TH 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 201 KB